Chemical Research in Chinese Universities ›› 2025, Vol. 41 ›› Issue (6): 1469-1484.doi: 10.1007/s40242-025-5231-5

• Reviews • Previous Articles     Next Articles

DNA Nanostructures-based Delivery of RNA Drugs for Cancer Therapy

WANG Jing1, WU Shuo1, YANG Dayong1,2, YAO Chi1   

  1. 1. State Key Laboratory of Synthetic Biology, Frontiers Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering, Ministry of Education, School of Synthetic Biology and Biomanufacturing, Tianjin University, Tianjin 300350, P. R. China;
    2. Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200438, P. R. China
  • Received:2025-09-30 Accepted:2025-10-30 Online:2025-12-01 Published:2025-12-05
  • Contact: YANG Dayong,E-mail:dayongyang@fudan.edu.cn;YAO Chi,E-mail:chi.yao@tju.edu.cn E-mail:dayongyang@fudan.edu.cn;chi.yao@tju.edu.cn
  • Supported by:
    This work was supported by the National Natural Science Foundation of China (Nos. 22225505, 22322407, 22535002, and W2412018). YANG Dayong thanks Fudan University (China) Ruiqing Education Funding.

Abstract: The emergence of RNA therapeutics, including antisense oligonucleotides, small interfering RNA, microRNA, messenger RNA and CRISPR-based systems, has revolutionized targeted cancer treatment by enabling precise gene regulation. However, their clinical translation is significantly hampered by inherent instability, inefficient cellular uptake, and potential immunogenicity. DNA-based nanostructures have recently emerged as highly programmable and biocompatible platforms for the efficient delivery of RNA therapeutics. This review comprehensively summarizes the recent advancements in DNA nanostructure-based delivery systems (e.g., DNA origami, tetrahedral frameworks) for RNA drugs, with a specific focus on cancer applications. We highlight the fundamental design principles of various DNA nanostructures and examine strategies for efficiently loading RNA payloads and achieving controlled, stimuli-responsive release (e.g., pH, ATP, enzymes) within the tumor microenvironment. The applications of these delivery systems in cancer gene therapy, immunotherapy, and combination regimens are extensively discussed. Finally, we address current challenges and future perspectives in the clinical translation of RNA drug delivery systems based on DNA nanostructures, emphasizing the need for improved stability, targeting specificity, and scalable preparation.

Key words: DNA nanotechnology, RNA therapeutics, Drug delivery system, Nanostructure, Cancer therapy